IGF-1R: A key linker between chemoresistance and cancer stem cells in epithelial ovarian cancer cells Ram Kumar Singh, Ankit Jinager, Ajit Dhadwe, Abhijit.

Slides:



Advertisements
Similar presentations
Triple negative breast cancer
Advertisements

Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.
Rare Tumour Working Group. Active Trials GOG 187 Phase 2 paclitaxel as 2 nd line therapy for ovarian stromal tumours-almost complete GOG239-Phase 2 AZD6244(MEK.
Stem Cells and Cell Signaling
Radioactive Iodine Refractory Patients : Definition and Treatment of Radioactive Iodine Refractory Thyroid Cancer Patients 방사성 옥소치료에 내성을 가진 갑상선암의 진단과 치료에.
‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.
Modulation of the Cellular Phenotype in Human Colon Adenocarcinoma Cells by Folic Acid and Polyamine Pools Nathan W. Sweeney, Julie A. Buckmeier, Christina.
Novel Drug Design Modified Megestrol by Group II.
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
Cancer Biology. 2 Outline 1.How do cancer cells differ from normal cells? Tumor progression Molecular basis for cancer.
 MicroRNAs (miRNAs) are a class of small RNA molecules, about ~21 nucleotide (nt) long.  MicroRNA are small non coding RNAs (ncRNAs) that regulate.
ADULT STEM CELL DR ANDUJAR LPGN RESEARCH SCIENTIST.
KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.
Targeted Therapy: A Giant Step Forward
HOXC6 and HOXC8 are potentially novel prognosis predictors of esophageal squamous cell carcinoma Keneng Chen, M.D., PhD, RCSF Luyan Shen, M.D., PhD 2015/4/28.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Inhibition of SHH signaling enhances Docetaxel efficacy in castration-resistant prostate cancer cells Sierra L. Lawhorne 1,2, Sakthivel Muniyan 1, Parthasarathy.
Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center Wichita,
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.
Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy.
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.
Cancer stem cells IOSI Journal Club Giulia Poretti January 19, 2007.
Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.
Lourdes Cortes-Dericks, PhD
MiR-19b/20a/92a regulates the self- renewal and proliferation of gastric cancer stem cells Journal of Cell Science (IF=5.325) 报告人:黄美玲
Calculus and Cancer Drug Development Studies Stephan Gysin, PhD UCSF Helen Diller Family Comprehensive Cancer Center.
Introduction The effects of HER2 gene and receptor over- expression on breast cancer. Prognosis and treatment of HER2+ breast cancer. (See figure 1)
Breast Cancer By: Christen Scott.
Infectivity Enhanced Adenovirus as a Strategy for Improving the Efficiency of RNA Interference in an Ovarian Cancer Model T Michael Numnum, MD International.
Acknowledgement of funding Regulator of G-protein signaling 5 blunts cellular viability mediated by a stabilized lysophosphatidic acid analogue (2S-OMPT)
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.
Potential therapeutic target & predictive biomarker Oncogenic IGFBP2 Sonya Song ( 宋韦 ) Beijing Shijitan Hospital Department of Oncology The Capital Medical.
Cell Suicide in Health and Disease
Telomerase, Immortalization and Cancer Eric Bankaitis Cancer Bio 169 March 9, 2006 Fig.[9]
Personalized Lung Cancer Treatment: Targeting Stem Cell Pathways David M. Jablons, M.D. Professor and Chief Thoracic Surgery Ada Distinguished Professor.
YEATS4 Is a Novel Oncogene Amplified in Non– Small Cell Lung Cancer That Regulates the p53 Pathway Speaker:Dai-Wei Hsuan Adviser:Dr. Guor-Mour, Her Data:2015/04/22.
Cancer Therapies DNA microarrays are used to assess the relative expression of thousands of genes simultaneously—relative expression means that.
Mothaffar F. Rimawi, Ingrid A. Mayer, Andres Forero, Rita Nanda, Matthew P. Goetz, Angel A. Rodriguez, Anne C. Pavlick, Tao Wang, Susan G. Hilsenbeck,
Pathology 430/827 Bladder cancer Etiology, classification, and diversity David M. Berman, MD, PhD Pathology and Molecular Medicine Queen’s Cancer Research.
Molecular Biomarkers & Targets an overview Michael Messenger NIHR Diagnostic Evidence Co-Operative & Leeds Cancer Research UK Centre.
Identification of Cancer Stem Cells using Flow Cytometry Analysis تعيين الخلايا الجذعية السرطانية باستخدام تحليل التدفق الخلوي Dr. Ayat Al-Ghafari Biochemistry.
XXV^ Riunione Nazionale MITO Innovation in gynecologic cancer: optimal therapy, quality of life, precision medicine. Naples, June Targeting.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
The role of regulatory B cells on hepatocellular carcinoma progression Conclusion Results Fig2. (A and B) In vivo, Bregs in SCID mice increased the size.
Cancer stem cells in solid tumors Laurie E Ailles and Irving L Weissman Stanford University School of Medicine Current opinion in biotechnology 2007,
YEATS4 Is a Novel Oncogene Amplified in Non– Small Cell Lung Cancer That Regulates the p53 Pathway Speaker:Dai-Wei Hsuan Adviser:Dr. Guor-Mour, Her Data:2015/04/22.
Lactate dehydrogenase is crucial for tumor associated macrophage protection of multiple myeloma cells against chemotherapy Carolyn Stierhoff, Enguang Bi,
Clinical and Research Updates in Gynecologic Oncology
SURGICAL ONCOLOGY AND TUMOR MARKERS
Opportunities for Addressing Unmet Clinical Need in Brain Cancer
Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?  Tony Sourisseau, PhD, Khaled.
Yu-fang huang, yi-hui wu, cheng-yang chou*
Med Princ Pract 2016;25(suppl 2): DOI: /
High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Cancer stem cells and their application into targeted therapy for cancer Mol. Bio. Lab Park Ji Won Supervisor ; Dae Youn Hwang.
Figure 1 A schematic representation of the HER2 signalling pathway
Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?  Tony Sourisseau, PhD, Khaled.
Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells  Nabanita Mukherjee, Josianna V. Schwan, Mayumi.
Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth
Cancer Stem Cells: Current Status and Evolving Complexities
Mohammed Charbat.
Giulia Tarantola, Humanitas University
Presentation transcript:

IGF-1R: A key linker between chemoresistance and cancer stem cells in epithelial ovarian cancer cells Ram Kumar Singh, Ankit Jinager, Ajit Dhadwe, Abhijit De and Pritha Ray* Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India 5 th Asia Pacific Summit on Cancer Therapy, 20 th – 22 nd July 2015

Ovarian Cancer  Ovarian cancer (OC) is the 4 th leading cause of gynecological deaths around the world. (Siegel et al., Cancer J Clin, 2012)  As per the Tata Memorial Center, Mumbai’s registry India, it is the third most lethal cancer amongst women. Types Germ cell OC (3-5%) Epithelial OC (85-90%) Sex-cord stromal cell OC (5-7%) Subtypes: Epithelial Ovarian Carcinoma Chemotherapy Platinum (cisplatin and carboplatin) Taxane (paclitaxel) Though the patients show response to 1 st line therapy, % ultimately exhibit recurrence and finally succumb to the disease.

Key players behind drug resistance There are subset of cells within the heterogeneous tumor designated as cancer stem cells. These CSCs have high DNA repair efficiency and chemo resistance property.

 Ovarian cancer-stem-like side population cells are tumorigenic and chemoresistant. (Hu et. al., British Journal of cancer, 2010)  In vivo and in vitro studies have showed the role of Insulin Growth Factor -1Receptor (IGF-1R) cross-talk in chemoresistance and have proven that IGF-1R inhibitors can overcome cytotoxic resistance. (Wong et. al., Gynecologic Oncology, 2012). Ovarian cancer and chemoresistance

Neoadjuvent therapy Debulking Surgery Adjuvant Chemotherapy Tumor Relapse Chemo resistance Tumor Relapse Chemo resistance Early detection of Chemo resistance Targeting Right population Cancer Stem Cells IGF-1R Axis

Schematic representation of development of cellular resistant models in A2780 cells

Understanding the role of the biological and molecular players during induction of drug resistance CSC characterization SP assay Biomarker assay Spheroid assay Tumor xenograft assay Cell line used A2780/APFT OAW42 SKOV3 Hey

Side population assay Cisplatin Model Paclitaxel Model Combination Model

Self Renewal and Chemoresistance Property A B C

Stemness gene expression across the resistant models

Biomarker analysis across the resistant models

Oct4 target Sequence adapted from Zaheres et al, Stem Cells, 2005 Knock down of Oct4 gene using pll3.7 lentilox vector

Effect of oct4 KD on its self renewal and drug resistance A Spheroid formation assay B Spheroid formation at multiple passage * P<0.05 ** P<0.005 *** P< D MTT assay to monitor drug resistance E Oct4 KD and P-AKT C Oct4 KD and SP phenotype

In vivo imaging of PAC ER SP/NSP cells for tumor formation

In vivo imaging of PAC LR SP/NSP cells for tumor formation SP Tumor Xenograft p/s/cm²/sr NSP Tumor Xenograft

In vivo imaging of CIS LR SP/NSP cells for tumor formation SP

IGF-1 -/- : Small Ovaries IGF1-R -/- : Infertile IGF Signaling in ovarian follicular development  The insulin-like growth factor (IGF) family is an essential growth factor system in the development of tissues or organs and postnatal growth, and maintenance of normal function of many cell types of the body (Li and Geng, 2010).  IGF may sustain the stem cell's capacity of self-renewal and differentiation, promote their survival and migration, and prevent senescence acting downstream to PI3K pathway (Li and Geng, 2010). Joanne s. Richards et al., Recent Prog Horm Res Is IGF-1R crucial for initiation and maintenance of resistance and stemness phenotype in ovarian cancer?

Elevated expression of IGF-1R at early stages of drug resistance A B C D Singh et. al., Cancer Letters, 2014

Inhibition of IGF-1R signaling with PPP PPP is a small molecule that selectively inhibits IGF-1R kinase activity without showing any effect against Insulin receptor and other RTKs. C Singh et. al., Cancer Letters, 2014

Potentiation of cytotoxicity using picropodophylin (PPP) Cisplatin Model Paclitaxel Model Combination Model Singh et. al., Cancer Letters, 2014

A B Effect of IGF-1R inhibition on long term survival of cells through clonogenic assay Singh et. al., Cancer Letters, 2014

Correlation between IGF-1R signaling and stemness phenotype How do late resistant cells maintain their resistant and stemness phenotype?

Effect of AKT inhibition on stemness property

Stemness/Chemoresistance IGF-1R AKT P Stemness/Chemoresistance IGF-1R Oct4 mRNA Early resistant stage Late resistant stage Regulation of stemness and chemoresistance at early and late resistant stage Active IGF-1R signalling Suppressed IGF-1R signalling AKT

25 Acknowledgement  ACTREC and UGC for Funding  UGC Fellowship